174 related articles for article (PubMed ID: 37733192)
1. Treatment Patterns by Race and Ethnicity in Newly Diagnosed Persons with Multiple Sclerosis.
Geiger CK; Sheinson D; To TM; Jones D; Bonine NG
Drugs Real World Outcomes; 2023 Dec; 10(4):565-575. PubMed ID: 37733192
[TBL] [Abstract][Full Text] [Related]
2. Real-World Clinical and Economic Outcomes Among Persons With Multiple Sclerosis Initiating First- Versus Second- or Later-Line Treatment With Ocrelizumab.
Geiger CK; Sheinson D; To TM; Jones D; Bonine NG
Neurol Ther; 2023 Oct; 12(5):1709-1728. PubMed ID: 37458897
[TBL] [Abstract][Full Text] [Related]
3. Treatment switches of disease-modifying therapies in people with multiple sclerosis: long-term experience from the German MS Registry.
Frahm N; Ellenberger D; Stahmann A; Fneish F; Lüftenegger D; Salmen HC; Schirduan K; Schaak TPA; Flachenecker P; Kleinschnitz C; Paul F; Krefting D; Zettl UK; Peters M; Warnke C
Ther Adv Neurol Disord; 2024; 17():17562864241239740. PubMed ID: 38560408
[TBL] [Abstract][Full Text] [Related]
4. Trajectories of disease-modifying therapies and associated sickness absence and disability pension among 1923 people with multiple sclerosis in Sweden.
Teni FS; Machado A; Murley C; He A; Fink K; Gyllensten H; Glaser A; Alexanderson K; Hillert J; Friberg E
Mult Scler Relat Disord; 2023 Jan; 69():104456. PubMed ID: 36529068
[TBL] [Abstract][Full Text] [Related]
5. Patterns of disease-modifying therapy utilization before, during, and after pregnancy and postpartum relapses in women with multiple sclerosis.
Bove R; Applebee A; Bawden K; Fine C; Shah A; Avila RL; Belviso N; Branco F; Fong K; Lewin JB; Liu J; England SM; Vignos M
Mult Scler Relat Disord; 2024 Jun; 88():105738. PubMed ID: 38959591
[TBL] [Abstract][Full Text] [Related]
6. Comparing ocrelizumab to interferon/glatiramer acetate in people with multiple sclerosis over age 60.
Foong YC; Merlo D; Gresle M; Buzzard K; Zhong M; Yeh WZ; Jokubaitis V; Monif M; Skibina O; Ozakbas S; Patti F; Grammond P; Amato MP; Kalincik T; Horakova D; Kubala Havrdova E; Weinstock-Guttman B; Lechner Scott J; Boz C; Sa MJ; Butzkueven H; van der Walt A; Zhu C;
J Neurol Neurosurg Psychiatry; 2024 Mar; ():. PubMed ID: 38453478
[TBL] [Abstract][Full Text] [Related]
7. COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies.
Reder AT; Centonze D; Naylor ML; Nagpal A; Rajbhandari R; Altincatal A; Kim M; Berdofe A; Radhakrishnan M; Jung E; Sandrock AW; Smirnakis K; Popescu C; de Moor C
CNS Drugs; 2021 Mar; 35(3):317-330. PubMed ID: 33743151
[TBL] [Abstract][Full Text] [Related]
8. Enrollment of Non-White Participants and Reporting of Race and Ethnicity in Phase III Trials of Multiple Sclerosis DMTs: A Systematic Review.
Onuorah HM; Charron O; Meltzer E; Montague A; Crispino A; Largent A; Lucas A; Freeman L
Neurology; 2022 Mar; 98(9):e880-e892. PubMed ID: 35046135
[TBL] [Abstract][Full Text] [Related]
9. Disease-modifying therapies and cost-of-illness progression among people newly diagnosed with multiple sclerosis: a national register-based cohort study covering treatment initiation with interferons, glatiramer acetate or natalizumab.
Karampampa K; Gyllensten H; Friberg E; Murley C; Kavaliunas A; Hillert J; Olsson T; Alexanderson K
BMJ Open; 2023 May; 13(5):e067516. PubMed ID: 37192793
[TBL] [Abstract][Full Text] [Related]
10. Association Between Disease-Modifying Therapies Prescribed to Persons with Multiple Sclerosis and Cancer: a WHO Pharmacovigilance Database Analysis.
Dolladille C; Chrétien B; Peyro-Saint-Paul L; Alexandre J; Dejardin O; Fedrizzi S; Defer G
Neurotherapeutics; 2021 Jul; 18(3):1657-1664. PubMed ID: 34231126
[TBL] [Abstract][Full Text] [Related]
11. Use of the new oral disease-modifying therapies for multiple sclerosis in British Columbia, Canada: the first five-years.
Setayeshgar S; Kingwell E; Zhu F; Zhang X; Zhang T; Marrie RA; Carruthers R; Tremlett H
Mult Scler Relat Disord; 2018 Oct; 25():57-60. PubMed ID: 30036855
[TBL] [Abstract][Full Text] [Related]
12. Indirect impact of the COVID-19 pandemic on the care and outcomes of people with MS: A combined survey and insurance claims study.
Meltzer E; Charron O; Wozny J; Onuorah H; Montague A; Kline AC; Largent A; Krause TM; Freeman L
Mult Scler Relat Disord; 2023 Dec; 80():105085. PubMed ID: 37931487
[TBL] [Abstract][Full Text] [Related]
13. Real-world disease-modifying therapy pathways from administrative claims data in patients with multiple sclerosis.
Fox RJ; Mehta R; Pham T; Park J; Wilson K; Bonafede M
BMC Neurol; 2022 Jun; 22(1):211. PubMed ID: 35672686
[TBL] [Abstract][Full Text] [Related]
14. Persistence, Adherence, and Switching to Higher-Cost Therapy in Patients with Multiple Sclerosis Initiating Oral Disease-Modifying Therapies: A Retrospective Real-World Study.
Araujo L; Geertsen SS; Amedume A; Higuchi K; van Wingerden J
Neurol Ther; 2022 Dec; 11(4):1735-1748. PubMed ID: 36152222
[TBL] [Abstract][Full Text] [Related]
15. Rituximab for people with multiple sclerosis.
Filippini G; Kruja J; Del Giovane C
Cochrane Database Syst Rev; 2021 Nov; 11(11):CD013874. PubMed ID: 34748215
[TBL] [Abstract][Full Text] [Related]
16. Antibodies against SARS-CoV-2 S and N proteins in relapsing-remitting multiple sclerosis patients treated with disease-modifying therapies.
Kulikowska J; Czarnowska A; Gudowska-Sawczuk M; Kulczyńska-Przybik A; Bazylewicz M; Collins F; Chorąży M; Mroczko B; Kochanowicz J; Kapica-Topczewska K; Kułakowska A
Neurol Neurochir Pol; 2023; 57(1):121-130. PubMed ID: 36421067
[TBL] [Abstract][Full Text] [Related]
17. Electronic health record data for assessing risk of hospitalization for COVID-19: Methodological considerations applied to multiple sclerosis.
Dillon P; Siadimas A; Roumpanis S; Fajardo O; Fitovski K; Jessop N; Whitley L; Muros-Le Rouzic E
Mult Scler Relat Disord; 2023 Mar; 71():104512. PubMed ID: 36716576
[TBL] [Abstract][Full Text] [Related]
18. Preliminary race-ethnicity-based analyses of fall risk among people with multiple sclerosis.
Buehler RA; Yang F
Mult Scler Relat Disord; 2023 Sep; 77():104857. PubMed ID: 37390677
[TBL] [Abstract][Full Text] [Related]
19. Risk of Getting COVID-19 in People With Multiple Sclerosis: A Case-Control Study.
Iaffaldano P; Lucisano G; Manni A; Paolicelli D; Patti F; Capobianco M; Brescia Morra V; Sola P; Pesci I; Lus G; De Luca G; Lugaresi A; Cavalla P; Montepietra S; Maniscalco GT; Granella F; Ragonese P; Vianello M; Brambilla L; Totaro R; Toscano S; Malucchi S; Petracca M; Moiola L; Ferraro D; Lepore V; Mosconi P; Ponzio M; Tedeschi G; Comi G; Battaglia MA; Filippi M; Amato MP; Trojano M;
Neurol Neuroimmunol Neuroinflamm; 2022 Mar; 9(2):. PubMed ID: 35046084
[TBL] [Abstract][Full Text] [Related]
20. Work Productivity Outcomes Associated with Ocrelizumab Compared with Other Disease-Modifying Therapies for Multiple Sclerosis.
Neuberger EE; Abbass IM; Jones E; Engmann NJ
Neurol Ther; 2021 Jun; 10(1):183-196. PubMed ID: 33244713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
